| 1.62 0.08 (5.19%) | 12-15 15:26 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.95 | 1-year : | 2.28 |
| Resists | First : | 1.67 | Second : | 1.95 |
| Pivot price | 1.5 |
|||
| Supports | First : | 1.5 |
Second : | 1.39 |
| MAs | MA(5) : | 1.52 |
MA(20) : | 1.51 |
| MA(100) : | 1.6  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 67.2 |
D(3) : | 48.9 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 3.47 | Low : | 1.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IKT ] has closed Bollinger Bands are 24.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.56 - 1.57 | 1.57 - 1.57 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.54 - 1.55 | 1.55 - 1.56 |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Sun, 14 Dec 2025
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald - MarketBeat
Thu, 11 Dec 2025
Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg - GuruFocus
Thu, 11 Dec 2025
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT) - MarketBeat
Mon, 08 Dec 2025
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance
Fri, 21 Nov 2025
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus
Thu, 20 Nov 2025
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 121 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 48.4 (%) |
| Shares Short | 4,140 (K) |
| Shares Short P.Month | 3,030 (K) |
| EPS | 0.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79.2 % |
| Return on Equity (ttm) | -131.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.26 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | 3.47 |
| PEG Ratio | 0 |
| Price to Book value | 1.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|